Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to α-synuclein

Neurochemistry International

Volumn 42, Issue 7, 2003, Pages 603-606

  Fasano, Mauro ^a   Giraudo, Sabrina ^b   Coha, Silvia ^b   Bergamasco, Bruno ^b,c   Lopiano, Leonardo ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c IRCCS   (Italy)

Author keywords

Synuclein; Lewy bodies; Neuromelanin; Parkinson's disease; Western blotting

Indexed keywords

ALPHA SYNUCLEIN; NEUROMELANIN;

ARTICLE; BIOACCUMULATION; CASE REPORT; CONTROLLED STUDY; EXTRACTION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LEWY BODY; NEUROPATHOLOGY; PARKINSON DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; SOLUBILIZATION; SUBSTANTIA NIGRA; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; MELANINS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; SUBSTANTIA NIGRA; SYNUCLEINS;

PARKINSONIA;

EID: 0037410207     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(02)00161-4     Document Type: Article

References (22)

1. Aime S., Fasano M., Terreno E., Groombridge C.J. NMR studies of melanins: characterization of a soluble melanin free acid (MFA) from sepia ink. Pigment Cell Res. 4:1991;216-221.
2. Aime S., Fasano M., Bergamasco B., Lopiano L., Valente G. Evidence for a glycid-lipidic matrix in human neuromelanin potentially responsible for the enhanced iron sequestering ability of substantia nigra. J. Neurochem. 62:1994;369-371.
3. 13C NMR characterization of an insoluble proteinaceous fraction from substantia nigra of Parkinson's disease patients Mov. Disord. 15:2000;977-981.
4. Borden K.L. Structure/function in neuroprotection and apoptosis. Ann. Neurol. 44:1998;S65-71.
5. Chung K.K., Zhang Y., Lim K.L., Tanaka Y., Huang H., Gao J., Ross C.A., Dawson V.L., Dawson T.M. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 7:2001;1144-1150.
6. Giasson B.I., Lee V.M. Parkin and the molecular pathways of Parkinson's disease. Neuron. 31:2001;885-888.
7. Halliwell, B., Gutteridge, J.M.C., 1989. Free Radicals in Biology and Medicine. Clarendon Press, Oxford.
8. Kanda S., Bishop J.F., Eglitis M.A., Yang Y., Mouradian M.M. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience. 97:2000;279-284.
9. Lang A.E., Lozano A.M. Parkinson's disease. N. Engl. J. Med. 339:1999;1044-1053.
10. Lopiano L., Chiesa M., Digilio G., Giraudo S., Bergamasco B., Torre E., Fasano M. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. Biochim. Biophys. Acta. 1500:2000a;306-312.
11. Lopiano L., Fasano M., Giraudo S., Digilio G., Bergamasco B., Torre E., Koenig S.H., Aime S. Nuclear magnetic relaxation dispersion profiles of substantia nigra pars compacta in Parkinson's disease patients are consistent with protein aggregation. Neurochem. Int. 37:2000b;331-336.
12. McNaught K.S., Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297:2001;191-194.
13. Mizuno Y., Hattori N., Kitada T., Matsumine H., Mori H., Shimura H., Kubo S., Kobayashi H., Asakawa S., Minoshima S., Shimizu N. Familial Parkinson's disease: alpha-synuclein and parkin. Adv. Neurol. 86:2001;13-21.
14. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., Kaufman S.A., Martin F., Sitney K., Denis P., Louis J.C., Wypych J., Biere A.L., Citron M. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274:1999;9843-9846.
15. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22:1999;123-144.
16. Orth M., Schapira A.H. Mitochondrial involvement in Parkinson's disease. Neurochem. Int. 40:2002;533-541.
17. Pocernich C.B., Cardin A.L., Racine C.L., Lauderback C.M., Butterfield D.A. Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem. Int. 39:2001;141-149.
18. Prota, G., 1992. Melanins and Melanogenesis. Academic Press, San Diego, CA.
19. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 293:2001;263-269.
20. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6469-6473.
21. Tabrizi S.J., Orth M., Wilkinson J.M., Taanman J.W., Warner T.T., Cooper J.M., Schapira A.H. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 9:2000;2683-2689.
22. Tofaris G.K., Layfield R., Spillantini M.G. Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509:2001;22-26.